Literature DB >> 28615245

The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Hong Ye1, Xiaofang Wang1, Megan M Constans1, Caroline R Sussman1, Fouad T Chebib1, María V Irazabal1, William F Young1, Peter C Harris1, Lawrence S Kirschner2, Vicente E Torres3.   

Abstract

The failure of the polycystins (PCs) to function in primary cilia is thought to be responsible for autosomal dominant polycystic kidney disease (ADPKD). Primary cilia integrate multiple cellular signaling pathways, including calcium, cAMP, Wnt, and Hedgehog, which control cell proliferation and differentiation. It has been proposed that mutated PCs result in reduced intracellular calcium, which in turn upregulates cAMP, protein kinase A (PKA) signaling, and subsequently other proliferative signaling pathways. However, the role of PKA in ADPKD has not been directly ascertained in vivo, although the expression of the main regulatory subunit of PKA in cilia and other compartments (PKA-RIα, encoded by PRKAR1A) is increased in a mouse model orthologous to ADPKD. Therefore, we generated a kidney-specific knockout of Prkar1a to examine the consequences of constitutive upregulation of PKA on wild-type and Pkd1 hypomorphic (Pkd1RC) backgrounds. Kidney-specific loss of Prkar1a induced renal cystic disease and markedly aggravated cystogenesis in the Pkd1RC models. In both settings, it was accompanied by upregulation of Src, Ras, MAPK/ERK, mTOR, CREB, STAT3, Pax2 and Wnt signaling. On the other hand, Gli3 repressor activity was enhanced, possibly contributing to hydronephrosis and impaired glomerulogenesis in some animals. To assess the relevance of these observations in humans we looked for and found evidence for kidney and liver cystic phenotypes in the Carney complex, a tumoral syndrome caused by mutations in PRKAR1A These observations expand our understanding of the pathogenesis of ADPKD and demonstrate the importance of PRKAR1A highlighting PKA as a therapeutic target in ADPKD.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  autosomal dominant polycystic kidney disease; cAMP; cell signaling; polycystic kidney disease; protein kinase A

Mesh:

Substances:

Year:  2017        PMID: 28615245      PMCID: PMC5625112          DOI: 10.1152/ajprenal.00119.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  52 in total

Review 1.  Hedgehog signalling.

Authors:  Raymond Teck Ho Lee; Zhonghua Zhao; Philip W Ingham
Journal:  Development       Date:  2016-02-01       Impact factor: 6.868

Review 2.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

3.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  Peptides from the PKD repeats of polycystin, the PKD1 gene product, modulate pattern formation in the developing kidney.

Authors:  J van Adelsberg
Journal:  Dev Genet       Date:  1999

5.  Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.

Authors:  Shan Qin; Mary Taglienti; Surya M Nauli; Leah Contrino; Ayumi Takakura; Jing Zhou; Jordan A Kreidberg
Journal:  J Clin Invest       Date:  2010-09-13       Impact factor: 14.808

6.  Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series.

Authors:  Diane Poster; Andreas D Kistler; Fabienne Krauer; Jon D Blumenfeld; Hanna Rennert; Dominik Weishaupt; Rudolf P Wüthrich; Andreas L Serra
Journal:  Am J Kidney Dis       Date:  2009-06-10       Impact factor: 8.860

7.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

Review 8.  Renal stone disease in autosomal dominant polycystic kidney disease.

Authors:  V E Torres; D M Wilson; R R Hattery; J W Segura
Journal:  Am J Kidney Dis       Date:  1993-10       Impact factor: 8.860

9.  Protein kinase A activation enhances β-catenin transcriptional activity through nuclear localization to PML bodies.

Authors:  Mei Zhang; Emilia Mahoney; Tao Zuo; Parmeet K Manchanda; Ramana V Davuluri; Lawrence S Kirschner
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

10.  Tissue-specific regulation of the mouse Pkhd1 (ARPKD) gene promoter.

Authors:  Scott S Williams; Patricia Cobo-Stark; Sachin Hajarnis; Karam Aboudehen; Xinli Shao; James A Richardson; Vishal Patel; Peter Igarashi
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-04
View more
  16 in total

Review 1.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

2.  Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

3.  Identification of clustered phosphorylation sites in PKD2L1: how PKD2L1 channel activation is regulated by cyclic adenosine monophosphate signaling pathway.

Authors:  Eunice Yon June Park; Misun Kwak; Kotdaji Ha; Insuk So
Journal:  Pflugers Arch       Date:  2017-12-11       Impact factor: 3.657

4.  Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.

Authors:  Sonu Kashyap; Kyaw Zaw Hein; Claudia Cs Chini; Jorgo Lika; Gina M Warner; Laurie K Bale; Vicente E Torres; Peter C Harris; Claus Oxvig; Cheryl A Conover; Eduardo N Chini
Journal:  JCI Insight       Date:  2020-02-27

Review 5.  Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.

Authors:  Mitchell I Parker; Anna S Nikonova; Danlin Sun; Erica A Golemis
Journal:  Cell Signal       Date:  2019-12-09       Impact factor: 4.315

Review 6.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

Review 7.  Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases.

Authors:  Emma T B Olesen; Robert A Fenton
Journal:  Nat Rev Nephrol       Date:  2021-07-01       Impact factor: 28.314

Review 8.  Renal Ciliopathies: Sorting Out Therapeutic Approaches for Nephronophthisis.

Authors:  Marijn F Stokman; Sophie Saunier; Alexandre Benmerah
Journal:  Front Cell Dev Biol       Date:  2021-05-13

9.  Targeting an anchored phosphatase-deacetylase unit restores renal ciliary homeostasis.

Authors:  Janani Gopalan; Mitchell H Omar; Ankita Roy; Nelly M Cruz; Jerome Falcone; Kiana N Jones; Katherine A Forbush; Jonathan Himmelfarb; Benjamin S Freedman; John D Scott
Journal:  Elife       Date:  2021-07-12       Impact factor: 8.140

10.  Integrative Cistromic and Transcriptomic Analyses Identify CREB Target Genes in Cystic Renal Epithelial Cells.

Authors:  Zhiheng Liu; Yunjing Liu; Lin Dang; Meijuan Geng; Yongzhan Sun; Yi Lu; Zhongze Fang; Hui Xiong; Yupeng Chen
Journal:  J Am Soc Nephrol       Date:  2021-06-23       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.